Beranda › Penyakit Pencernaan › Texas
Uji klinis Penyakit Pencernaan di Texas
13 studi untuk Penyakit Pencernaan mencari peserta di lokasi di Texas.
Kota di Texas
- Houston8 studi
- San Antonio5 studi
- Tyler5 studi
- Austin4 studi
- Lewisville4 studi
- Dallas4 studi
- Fort Worth3 studi
- El Paso3 studi
- Amarillo3 studi
Teks studi resmi (Bahasa Inggris)
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Inquest Clinical Research, Baytown
- DHR Health Gastroenterology - Edinburg, Edinburg
- Baylor College of Medicine, Houston
- dan 3 lainnya
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06598943Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Texas Oncology - West Texas, Abilene
- Texas Oncology - West Texas, Amarillo
- Texas Oncology - Gulf Coast, Beaumont
- dan 27 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07222800Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
- Texas Liver Institute, San Antonio
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07654283Product Surveillance Registry
- Austin
- Dallas
- Fort Worth
- dan 6 lainnya
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT01524276Feasibility Study of a Guided Imagery Therapy Mobile Application for Functional Abdominal Pain Disorders in Children
- Baylor College of Medicine/Texas Children's Hospital, Austin
- Baylor College of Medicine / Texas Children's Hospital, Houston
Menerima peserta
Usia 7 hingga 12 · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07222943A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Amarillo
- 89bio Clinical Study Site, Austin
- 89bio Clinical Study Site, Austin
- dan 30 lainnya
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Amarillo
- 89bio Clinical Study Site, Austin
- 89bio Clinical Study Site, Austin
- dan 21 lainnya
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06419374Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
- University of Texas Health Science Center at Houston, Houston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07351071Advanced GastroInstestinal(GI) Surgery Training in Residency and Fellowship.
- Methodist Dallas Medical Center- Clinical Research Institute, Dallas
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT07494318Evaluation of Hepato-Pancreato-Biliary
- Methodist Dallas Medical Center- Clinical Research Institute, Dallas
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Semua usia · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT07565454GpCRC Pediatric Gastroparesis Registry 2
- Texas Tech University Health Science Center, El Paso
- Baylor College of Medicine/Texas Children's Hospital, Houston
Menerima pesertaStudi observasional
Usia 8 hingga 25 · Semua jenis kelamin · Diperbarui 3 Apr 2026 · NCT05981300Gastroparesis Registry 4
- Texas Tech University Health Science Center (TTUHSC), El Paso
Menerima pesertaStudi observasional
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 3 Apr 2026 · NCT05846802Endoscopic Retrograde Cholangiopancreatography
- Methodist Dallas Medical Center- Clinical Research Institute, Dallas
Menerima pesertaStudi observasional
Usia 15 ke atas · Semua jenis kelamin · Diperbarui 24 Mar 2026 · NCT07490132Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.